嘉和美康（北京）科技股份有限公司2025年度业绩快报公告

Financial Performance Summary - In 2025, the company achieved operating revenue of 407.67 million RMB, a decrease of 31.13% compared to the previous year [3] - The net profit attributable to the parent company was -252.78 million RMB, a reduction in losses by 3.34 million RMB year-on-year [3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -257.10 million RMB, a reduction in losses by 4.28 million RMB year-on-year [3] Asset and Equity Status - As of the end of the reporting period, total assets amounted to 2,141.03 million RMB, a year-on-year decrease of 13.92% [2] - The equity attributable to the parent company was 1,301.97 million RMB, down 16.29% year-on-year [2] - The net asset per share attributable to the parent company was 9.46 RMB, a decrease of 16.29% year-on-year [2] Factors Affecting Performance - The decline in revenue was primarily due to reduced or delayed fiscal budget support for public hospitals' medical information construction, leading to compressed procurement demand [4] - The implementation of medical insurance payment reforms resulted in decreased income and profit margins for public hospitals, making them more cautious in software procurement [4] - The overall tightening of demand due to macroeconomic and policy influences led to weakened customer purchasing intent, significantly impacting the company's revenue [5] Research and Development Investment - The company maintained high levels of R&D investment despite implementing cost control measures, focusing on enhancing core products in response to market opportunities in AI applications [4] - New products, such as the Goodwill-Fusion data integration platform, are still in the market adjustment phase and have not yet contributed significantly to revenue [4] - The ongoing high R&D expenditure, in the context of declining revenue, has further pressured profit margins [4]